Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

B&L’s MoistureLoc Worldwide Recall: Firm Ties Formulation To Infection

This article was originally published in The Gray Sheet

Executive Summary

With evidence pointing to the basic formulation of Bausch & Lomb's ReNu with MoistureLoc contact lens solution as a contributing factor in an outbreak of serious eye infections, the company bit the bullet May 15 and issued a permanent, worldwide recall of the lucrative product

You may also be interested in...



FDA Is Revising Contact-Lens Guidelines To Protect Against Infections

The agency’s ophthalmic device advisory panel is meeting in May to address FDA’s plans to revise guidance documents describing 510(k) submissions for contact lenses and lens care products. The changes would incorporate lessons learned since the infectious outbreaks linked to multipurpose contact lens solution in the past decade.

AMO Lens Solution Recall Will Cut Sales By Up To $120 Million In 2007

The fallout from Advanced Medical Optics' May recall of its Complete MoisturePlus multipurpose contact lens solution will include lost sales of $100 million to $120 million this year, the firm projects

AMO Lens Solution Recall Will Cut Sales By Up To $120 Million In 2007

The fallout from Advanced Medical Optics' May recall of its Complete MoisturePlus multipurpose contact lens solution will include lost sales of $100 million to $120 million this year, the firm projects

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel